Literature DB >> 28577874

RAS Genetic Variants in Interaction with ACE Inhibitors Drugs Influences Essential Hypertension Control.

Farzad Heidari1, Ramachandran Vasudevan2, Siti Zubaidah Mohd Ali3, Patimah Ismail4, Mohammad Arkani4.   

Abstract

BACKGROUNDS AND AIMS: Essential Hypertension (EH) is a common disorder associated with increased cardiovascular morbidity and mortality in Malaysia. To investigate how genetic polymorphisms of the renin-angiotensin-aldosterone system (RAS) influence EH control with angiotensin-converting enzyme inhibitor drugs (ACEI).
METHODS: A case-control, cross-sectional population-based nested study (n = 142) included hypertensive subjects treated with ACEI drugs, either lisinopril or enalapril (20 mg, once daily) as monotherapy for 24 weeks. In total seven possible polymorphisms of RAS genes were genotyped. The association between those polymorphisms and the changes in blood pressure were observed in the 24 week treatment.
RESULTS: Statistically significant associations of I, G, T, M and G alleles of ACE (I/D, G2350A), AGT (M235T, T175M and G-6A) respectively were observed in essential hypertensive subjects. The decrease in systolic blood pressure and diastolic blood pressure after 24 weeks of treatment of the patients carrying II, GG, and TT genotypes were greater than the groups carrying DD, AA, MM, MM and GG of I/D, G2350A, M235T, T174M and G-6A genotypes respectively. In contrast, No significant difference was observed between renin gene polymorphisms (Bg/I and MboI) and hypertensives.
CONCLUSIONS: Although this study shows a possible association of polymorphisms of RAS genes with the risk of non-control of HT in ACEI-treated patients and indicates the importance of all this system's components in regulating HT, it needs to be replicated in other data sources.
Copyright © 2017 IMSS. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Enalapril; Gene polymorphism; Lisinopril; Pharmacogenetics Hypertension; Renin-angiotensin-aldosterone System

Mesh:

Substances:

Year:  2017        PMID: 28577874     DOI: 10.1016/j.arcmed.2017.03.003

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  6 in total

Review 1.  Genetics of Human Primary Hypertension: Focus on Hormonal Mechanisms.

Authors:  Worapaka Manosroi; Gordon H Williams
Journal:  Endocr Rev       Date:  2019-06-01       Impact factor: 19.871

Review 2.  Hypertension: a new treatment for an old disease? Targeting the immune system.

Authors:  Gisele Facholi Bomfim; Stefany Bruno Assis Cau; Alexandre Santos Bruno; Aline Garcia Fedoce; Fernando S Carneiro
Journal:  Br J Pharmacol       Date:  2018-07-31       Impact factor: 8.739

Review 3.  Pharmacogenetics in Primary Headache Disorders.

Authors:  Irina I Belyaeva; Anna G Subbotina; Ivan I Eremenko; Vadim V Tarasov; Vladimir N Chubarev; Helgi B Schiöth; Jessica Mwinyi
Journal:  Front Pharmacol       Date:  2022-02-10       Impact factor: 5.810

4.  Identification and Molecular Docking Study of a Novel Angiotensin-I Converting Enzyme Inhibitory Peptide Derived from Enzymatic Hydrolysates of Cyclina sinensis.

Authors:  Fangmiao Yu; Zhuangwei Zhang; Liwang Luo; Junxiang Zhu; Fangfang Huang; Zuisu Yang; Yunping Tang; Guofang Ding
Journal:  Mar Drugs       Date:  2018-10-27       Impact factor: 5.118

5.  The Association Between Selected Molecular Biomarkers and Ambulatory Blood Pressure Patterns in African Chronic Kidney Disease and Hypertensive Patients Compared With Normotensive Controls: Protocol for a Longitudinal Study.

Authors:  Abiodun Moshood Adeoye; Oladimeji Adebayo; Busayo Abiola; Bamidele Iwalokun; Bamidele Tayo; Fadi Charchar; Akinlolu Ojo; Richard Cooper
Journal:  JMIR Res Protoc       Date:  2020-01-17

6.  Association between angiotensin converting enzyme gene polymorphism and essential hypertension: A systematic review and meta-analysis.

Authors:  Mingyu Liu; Jian Yi; Wenwen Tang
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2021 Jan-Dec       Impact factor: 1.636

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.